Novel effective treatment is direly needed for patients with pancreatic ductal
adenocarcinoma (PDAC). Therapeutics that target the driver mutations, especially the KRAS …

Pancreatic ductal adenocarcinoma (PDAC) remains a lethal cancer. The poor prognosis
calls for a more detailed understanding of disease biology in order to pave the way for the …

Pancreatic adenocarcinoma is a highly lethal disease that is histologically characterized by
a dense desmoplastic reaction (DR) surrounding malignant epithelial cells. The DR is …

Pancreatic ductal adenocarcinoma (PDA) is notoriously aggressive and hard to treat. The
tumour microenvironment (TME) in PDA is highly dynamic and has been found to promote …

Simple Summary This review depicts the principal mechanisms involved in the process of
stromal desmoplasia characterizing pancreatic ductal adenocarcinoma (PDAC). The aim of …

Simple Summary Pancreatic cancer is a highly malignant disease with treatment resistance
to standardized chemotherapies. In addition, only a small fraction of patients with pancreatic …

Simple Summary Pancreatic ductal adenocarcinoma's (PDAC) dismal prognosis is
associated with its aggressive biological behavior and resistance to chemotherapy …

Pancreatic ductal adenocarcinoma (PDAC) is increasing in incidence and is projected to
become the second leading cause of cancer death in the United States. Despite significant …

Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with high morbidity and
mortality worldwide. To date, limited therapeutic achievements targeting cell proliferation …

Pancreatic ductal adenocarcinoma (PDAC) is characterised by an abundant stromal
response also known as a desmoplastic reaction. Pancreatic Stellate Cells have been …